Showing 2931-2940 of 5771 results for "".
- Ocugen Reports Positive Preliminary Data from OCU410 Trial for Geographic Atrophyhttps://modernod.com/news/ocugen-reports-positive-preliminary-data-from-ocu410-trial-for-geographic-atrophy/2482550/Ocugen announced encouraging preliminary results from the phase 1 portion of its phase 1/2 OCU410 ArMaDa clinical trial for geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). The trial, which includes nine patients across three dose cohorts, revealed promis
- Alkeus Secures Rare Pediatric Disease and Fast Track FDA Designations for Gildeuretinol in Stargardt Diseasehttps://modernod.com/news/alkeus-secures-rare-pediatric-disease-and-fast-track-fda-designations-for-gildeuretinol-in-stargardt-disease/2482549/Alkeus Pharmaceuticals announced that its investigational oral therapy, gildeuretinol (ALK-001), has been granted Rare Pediatric Disease and Fast Track designations by the FDA for the treatment of Stargardt disease. “Stargardt disease imposes a relentless burden, robbing chil
- Ophtec Receives CE Mark Approval for Artiplus Phakic IOL for Presbyopiahttps://modernod.com/news/ophtec-receives-ce-mark-approval-for-artiplus-phakic-iol-for-presbyopia/2482548/Ophtec announced it has received CE Mark approval for its Artiplus Phakic IOL, which is designed for young presbyopes, typically in their early 40s. The Artiplus lens is designed to provide clear vision at all distances, eliminating the need for reading glasses or other corrective
- FDA Accepts Aldeyra's NDA for Reproxalap in Dry Eye Disease; Expands Partnership with AbbViehttps://modernod.com/news/fda-accepts-aldeyras-nda-for-reproxalap-in-dry-eye-disease/2482547/Aldeyra Therapeutics announced that the FDA has officially accepted for review the resubmitted new drug application (NDA) for its topical ocular therapy, reproxalap, aimed at treating the signs and symptoms of dry eye disease. The FDA has set a Prescription Drug User Fee Act (PDUFA) target d
- Eyenovia's Late-Stage Pediatric Myopia Treatment Fails to Meet Primary Endpointhttps://modernod.com/news/eyenovias-late-stage-pediatric-myopia-treatment-fails-to-meet-primary-endpoint/2482544/Eyenovia announced that its phase 3 CHAPERONE study failed to meet its primary endpoint. The study was investigating Eyenovia’s proprietary drug-device combination, using low-dose atropine dispensed through the company's Optejet platform, as a potential treatment for pediatric
- Bausch + Lomb’s Recycling Programs Collect Over 94 Million Units of Eye Care Waste in the UShttps://modernod.com/news/bausch-lombs-recycling-programs-collect-over-94-million-units-of-eye-care-waste-in-the-us/2482541/Bausch + Lomb announced a milestone in its sustainability efforts—the company's exclusive recycling initiatives, ONE by ONE Recycling and Biotrue Eye Care Recycling programs, have successfully collected a total of 94,119,275 units of used contact lenses, eye care, and lens care material
- Kian Capital and RF Investment Partners to Launch US VisionMed Partnershttps://modernod.com/news/kian-capital-and-rf-investment-partners-to-launch-us-visionmed-partners/2482540/Kian Capital Partners and RF Investment Partners, two private investment firms, have announced the launch of US VisionMed Partners, a management services organization (MSO). US VisionMed Partners aims to elevate optometry practices by offering a unique model focused on medically advance
- Harrow Launches Initiative to Expand Access and Affordability for Eye Care Medicationshttps://modernod.com/news/harrow-launches-initiative-to-expand-access-and-affordability-for-eyecare-medications/2482538/Harrow announced an initiative aimed at enhancing access and affordability for its ophthalmic pharmaceutical products. This program includes targeted price reductions for several widely used Harrow products, along with a strategic partnership with prescription savings platform GoodRx. <
- Harrow Secures Medicare Part D Market Access for Vevyehttps://modernod.com/news/harrow-secures-medicare-part-d-market-access-for-vevye/2482535/Harrow announced that beginning January 1, 2025, Harrow’s dry eye disease treatment, Vevye, will be included in the formularies of major plan sponsors, including Express Scripts, Cigna, Kaiser Permanente, and CVS Caremark. Collectively, these plan sponsors provide coverage for more tha
- Konan Medical USA Launches objectiveFIELD Visual Field Analyzerhttps://modernod.com/news/konan-medical-usa-launches-objectivefield-visual-field-analyzer/2482534/Konan Medical USA announced the commercial launch of its objectiveFIELD (OFA) visual field analyzer. The OFA is an objective visual field analyzer designed to detect visual field abnormalities using pupillary responses. According to Konan Medical, unlike traditional subjectiv